Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Estrogen Receptors in Health and Disease


Affiliations
1 Division of Biochemistry, CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow-226031, India
2 Division of Endocrinology and Center for Research on Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow-226031, India
     

   Subscribe/Renew Journal


Estrogen signalling is a balance between two closely related transcription factors (TFs), the estrogen receptors (ERα and ERβ), both of which bind to similar DNA element called estrogen response element (ERE). ERs do not function by themselves but require a number of co-regulatory proteins (SRC1, A1, NCoR) whose cell-speciuc expression elucidates some of the divergent cellular actions of estrogen. A considerable body of evidence has shown that over-expression of ERα leads to uncontrolled cell growth and proliferation resulting in carcinomas of breast, ovary, uterus and prostate while ERβ down-regulation causes colon cancer. ERs are well-known regulators of several aspects of metabolism, including glucose and lipid metabolism, whereas impaired estrogen signalling is associated with the development of metabolic bone disorders as in post-menopausal women. We review new evidences depicting the importance of ER in understanding the normal physiological functions and how the disruption of typical estrogen signalling leads to the development and progression of various forms of endocrine cancers and metabolic disorders including post-menopausal osteoporosis, diabetes and obesity. Re-examination of available therapies will enable us to therapeutically address fundamental issues towards the design of pharmacologic molecules so as to target crucial metabolic cascades and genes.

Keywords

Estrogen Receptor, Cancer, Osteoporosis, Diabetes, Obesity, SERMs.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 249

PDF Views: 0




  • Estrogen Receptors in Health and Disease

Abstract Views: 249  |  PDF Views: 0

Authors

Anagha Gurjar
Division of Biochemistry, CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow-226031, India
Kainat Khan
Division of Endocrinology and Center for Research on Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow-226031, India
Manisha Yadav
Division of Biochemistry, CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow-226031, India
Harish Kumar
Division of Biochemistry, CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow-226031, India
Naibedya Chattopadhyay
Division of Endocrinology and Center for Research on Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow-226031, India
Sabyasachi Sanyal
Division of Biochemistry, CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow-226031, India

Abstract


Estrogen signalling is a balance between two closely related transcription factors (TFs), the estrogen receptors (ERα and ERβ), both of which bind to similar DNA element called estrogen response element (ERE). ERs do not function by themselves but require a number of co-regulatory proteins (SRC1, A1, NCoR) whose cell-speciuc expression elucidates some of the divergent cellular actions of estrogen. A considerable body of evidence has shown that over-expression of ERα leads to uncontrolled cell growth and proliferation resulting in carcinomas of breast, ovary, uterus and prostate while ERβ down-regulation causes colon cancer. ERs are well-known regulators of several aspects of metabolism, including glucose and lipid metabolism, whereas impaired estrogen signalling is associated with the development of metabolic bone disorders as in post-menopausal women. We review new evidences depicting the importance of ER in understanding the normal physiological functions and how the disruption of typical estrogen signalling leads to the development and progression of various forms of endocrine cancers and metabolic disorders including post-menopausal osteoporosis, diabetes and obesity. Re-examination of available therapies will enable us to therapeutically address fundamental issues towards the design of pharmacologic molecules so as to target crucial metabolic cascades and genes.

Keywords


Estrogen Receptor, Cancer, Osteoporosis, Diabetes, Obesity, SERMs.



DOI: https://doi.org/10.18519/jer%2F2013%2Fv17%2F75682